Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.83 |
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.56 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.55 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.55 |
| ▸ | GSR | P00390 | 1/20 | 0.52 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.50 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15739372 | 0.91 | FOLH1 (1.00) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL2450656 | 0.91 | FOLH1 (1.00) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL2450650 | 0.91 | FOLH1 (1.00) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL4669761 | 0.91 | FOLH1 (1.00) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL15739351 | 0.91 | FOLH1 (1.00) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL23839908 | 0.91 | FOLH1 (0.87) | FOLH1CPB2RIMKLANAALAD2SLC6A5 | |
| SCHEMBL15739333 | 0.91 | FOLH1 (1.00) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL1741931 | 0.91 | FOLH1 (1.00) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL20844296 | 0.91 | FOLH1 (0.76) | FOLH1CPB2RIMKLANAALAD2SLC6A5 | |
| SCHEMBL19352015 | 0.89 | FOLH1 (0.97) | FOLH1RIMKLANAALAD2SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964640-B2 | Oligomers of straight-chain and unbranched fatty acids and drugs containing these | PLT PATENT & LICENSE TRADING LTD. (GB) | 2011-06-21 | — | — | US | disclosed |
| US-7964640-B2 | Oligomers of straight-chain and unbranched fatty acids and drugs containing these | PLT PATENT & LICENSE TRADING LTD. (GB) | 2011-06-21 | — | — | US | disclosed |
| EP-2216319-A2 | Oligomers of straight-chain and unbranched fatty acids, and medicaments containing the same | PLT Patent & Licence Trading Ltd. (GB) | 2010-08-11 | — | — | EP | disclosed |
| US-20090012166-A1 | Oligomers of Straight-Chain and Unbranched Fatty Acids and Drugs Containing These | PLT PATENT & LICENSE TRADING S.L. (ES) | 2009-01-08 | — | — | US | disclosed |
| US-20090012166-A1 | Oligomers of Straight-Chain and Unbranched Fatty Acids and Drugs Containing These | PLT PATENT & LICENSE TRADING S.L. (ES) | 2009-01-08 | — | — | US | disclosed |
| WO-2007006550-A2 | OLIGOMERS OF STRAIGHT-CHAIN AND UNBRANCHED FATTY ACIDS, AND MEDICAMENTS CONTAINING THE SAME | PLT PATENT & LICENCE TRADING LTD. (GB) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012166-A1 | Oligomers of Straight-Chain and Unbranched Fatty Acids and Drugs Containing These | FASN, FFAR3, FFAR2 | FOLH1 1781/4885CPB2 3923/4885RIMKLA 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.